An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
Background. Alirocumab and evolocumab, as protein convertase subtilisin kexin type 9 (PCSK9) inhibitors, have been reported to reduce cardiovascular risk. This meta-analysis is aimed at updating the safety data of PCSK9 inhibitors. Methods. We assessed the relative risk for all treatment-related adv...
| Published in: | Cardiovascular Therapeutics |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2023/7362551 |